Suppr超能文献

他汀类药物对持续性心房颤动电复律后维持窦性心律的影响。

Lack of effect of statins on maintenance of normal sinus rhythm following electrical cardioversion of persistent atrial fibrillation.

机构信息

University of Connecticut Schools of Medicine and Pharmacy, Farmington and Storrs, CT, USA.

出版信息

Int J Clin Pract. 2010 Jul;64(8):1116-20. doi: 10.1111/j.1742-1241.2010.02387.x.

Abstract

Randomised controlled trials evaluating the effect of statin use on maintenance of normal sinus rhythm (NSR) after electrical cardioversion (ECV) of persistent atrial fibrillation (AF) have demonstrated conflicting results. However, many of these trials were of relatively small size and thus underpowered to adequately evaluate this end-point. The aim of this study was to conduct a meta analysis evaluating the effect of statin use on maintenance of NSR after ECV of persistent AF. Randomised controlled trials evaluating the use of statins to maintain NSR after ECV of AF were identified through a systematic search including Medline (1950 through December 2009), the Cochrane CENTRAL Register (4th quarter, 2009) and a manual review of references without any language restrictions. Pooled estimates of effect are reported as relative risks (RRs) with accompanying 95% confidence intervals (CIs) using a random-effects model. Four trials (n = 424; range: 48-212) were identified and subject to meta analysis. Evaluated statins included atorvastatin 10 and 80 mg and pravastatin 40 mg/day. Over a mean of 2.1 months (range: 1-3 months) statins did not increase the likelihood of maintaining NSR following ECV (RR, 1.12; 95%CI, 0.85-1.46) compared with control. Current evidence does not suggest that statins are associated with an increased probability of maintaining NSR following ECV of persistent AF.

摘要

随机对照试验评估他汀类药物对持续性心房颤动(AF)电复律(ECV)后维持窦性心律(NSR)的影响,结果相互矛盾。然而,这些试验大多规模较小,因此不足以充分评估这一终点。本研究的目的是进行荟萃分析,评估他汀类药物对持续性 AF 电复律后维持 NSR 的影响。通过系统搜索,包括 Medline(1950 年至 2009 年 12 月)、Cochrane 中心注册库(2009 年第 4 季度)和参考文献的手工审查,确定了评估他汀类药物用于维持 AF 电复律后 NSR 的随机对照试验,没有任何语言限制。使用随机效应模型,报告合并效应的估计值为相对风险(RR)及其伴随的 95%置信区间(CI)。确定了四项试验(n=424;范围:48-212)进行荟萃分析。评估的他汀类药物包括阿托伐他汀 10 和 80 mg 以及普伐他汀 40 mg/天。在平均 2.1 个月(范围:1-3 个月)的时间内,与对照组相比,他汀类药物并没有增加 ECV 后维持 NSR 的可能性(RR,1.12;95%CI,0.85-1.46)。目前的证据表明,他汀类药物与持续性 AF 电复律后维持 NSR 的可能性增加无关。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验